Context • N-of-1 trials are multiple crossover trials with randomized and blinded methods, conducted with a single participant to evaluate the effectiveness and safety of a therapy. They can be a helpful tool for enriching clinical research for traditional Chinese medicine (TCM), but the approach has gained little traction in TCM. Information is needed before supporters of the trials can pursue a change to that status. Objective • The study intended to obtain data needed to support TCM clinicians' adoption of N-of-1 trials. Methods • TCM clinicians were interviewed using a dedicated questionnaire between May 15, 2014, and July 31, 2014. Setting • The study took place at 4 teaching hospitals (Lanzhou City, China). Participants • Participants were TCM clinicians at the 4 hospitals. Outcome Measures • The survey included questions to obtain information on (1) the various methods that the TCM physicians used to obtain information about how to develop and conduct clinical trials, (2) their knowledge and experience with traditional clinical trials, (3) their awareness of the concept and methodology of N-of-1 trials, and (4) their needs and willingness to receive training about such trials. Descriptive statistics were used. Results • One-hundred-and-six clinicians, with a median age of 32 ± 9 y, participated in the survey. Most received information on research methods from a medical database (77%) or academic conferences (65%). Eighty-two percent of the clinicians had read papers about clinical trials, and 84% of the material read were medical articles in Mandarin. Of the participants, 57% had designed and carried out clinical trials during the 5 y before the survey, and among those participants, 26% had performed randomized controlled trials (RCTs), 28% had carried out retrospective studies, 16% had conducted observational studies, and 30% had completed case reports. For those studies, the results of 7% had been published in the Science Citation Index (SCI), 47% in the Chinese Science Citation Database (CSCD), and 31% in provincial journals; 15% were unpublished. Only 37% had heard of an N-of-1 trial, and only 5% understood what the term means. Most intermediate clinicians thought it is necessary to train different groups of clinicians using N-of-1 trials that included clinicians and patients. Conclusions • The results highlight the possible interest of TCM clinicians in the methods of N-of-1 trials; meanwhile, the study's data stress the need for appropriate medical education and recommendations based on available evidence. Further efforts in the area should emphasize the benefits for patients and funders. The training is necessary in TCM clinical practice to improve the evidence quality of studies on TCM.
Download full-text PDF |
Source |
---|
Well-designed effective interventions promoting sustainable diets are urgently needed to benefit both human and planetary health. This study evaluated the feasibility, acceptability, and potential impact of a pilot blended digital intervention aimed at promoting sustainable diets. We conducted a series of ABA n-of-1 trials with baseline, intervention, and follow-up phases over the course of a year, involving twelve participants.
View Article and Find Full Text PDFZhonghua Yi Xue Yi Chuan Xue Za Zhi
January 2025
University of Hong Kong Shenzhen Hospital, Shenzhen, Guangdong 518053, China.
Antisense oligonucleotide (ASO) was discovered several decades ago and initially used only as a research tool in the laboratory. In recent years, several ASO therapeutics have been developed for neurological disorders. Some of these therapeutics, including eteplirsen, golodirsen, viltolarsen, nusinersen and inotersen, have been approved by the Food and Drug Administration (FDA) and begun to draw the public's attention as an effective therapeutic approach.
View Article and Find Full Text PDFJ Neurogastroenterol Motil
January 2025
Department of Gastroenterology, St Mark's Hospital, London, UK.
Background/aims: Buspirone shows promise in treating disorders of gut-brain interaction (DGBIs), particularly functional dyspepsia. However, findings have been mixed.
Methods: We systematically searched for prospective studies testing buspirone for any upper gastrointestinal DGBI in 4 databases (Cochrane, PubMed, Scopus, and PsycInfo).
Clin Trials
January 2025
Department of Biostatistics, University of Washington, Seattle, WA, USA.
Background: N-of-1 trials compare two or more treatment options for a single participant. These trials have been used to study options for chronic conditions such as arthritis and attention deficit hyperactivity disorder. In addition, they have been suggested as a means to study interventions in rare populations that may not be tractable to include in standard clinical trials, such as treatment options for HIV-positive patients in need of organ transplant.
View Article and Find Full Text PDFJ Med Genet
December 2024
Department of Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands
Background: Clinical trials for rare disorders have unique challenges due to low prevalence, patient phenotype variability and high expectations. These challenges are highlighted by our study on clonazepam in patients, a common cause of intellectual disability. Previous studies on Arid1b-haploinsufficient mice showed positive effects of clonazepam on various cognitive aspects.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!